Vaginal Cancer - Pipeline Review, H2 2011

Global Markets Direct, August 2011, Pages: 42

Vaginal Cancer - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Vaginal Cancer - Pipeline Review, H2 2011', provides an overview of the Vaginal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Vaginal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vaginal Cancer. 'Vaginal Cancer - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Vaginal Cancer.
- A review of the Vaginal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Vaginal Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Vaginal Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Vaginal Cancer pipeline depth and focus of Vaginal Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Vaginal Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Vaginal Cancer
Vaginal Cancer Therapeutics under Development by Companies
Vaginal Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Vaginal Cancer Therapeutics - Products under Development by Companies
Vaginal Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Vaginal Cancer Therapeutics Development
Merck & Co., Inc.
Vaginal Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
V503 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vinorelbine + Paclitaxel + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fondaparinux Sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V502 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V504 + Gardasil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V505 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Therapeutic allogeneic Lymphocytes + Cyclosporine + Fludarabine Phosphate + Mycophenolate Mofetil + Stem Cell Transplantation + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triapine + Cisplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Topotecan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaginal Cancer Therapeutics – Drug Profile Updates
Vaginal Cancer Therapeutics - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Vaginal Cancer, H2 2011
Products under Development for Vaginal Cancer – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Merck & Co., Inc., 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Vaginal Cancer Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Vaginal Cancer, H2 2011
Products under Development for Vaginal Cancer – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Acute Pain - Pipeline Review, H2 2012
• Lip Cancer - Pipeline Review, H2 2012
• Male Cancer - Pipeline Review, H2 2012
• Pediatric Cancer - Pipeline Review, H2 2012
• Metastatic Colorectal Cancer - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Bladder Cancer - Pipeline Review, H2 2012
• Anaplastic Thyroid Cancer - Pipeline Review, H2 2012
• Metastatic Prostate Cancer - Pipeline Review, H2 2012
• Mycoses - Pipeline Review, H2 2012